Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABAPLAST: GABAergic treatments and cortical plasticity after subacute stroke
2026-526884-39-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2026
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of baclofen, gabapentin and oxazepam in stroke (3 cohorts), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in PAS-induced motor evoked potential amplitude. Planned start Sep 2026; status: authorised.
02
Drugs
baclofengabapentinoxazepam
03
Conditions
stroke
Beyond the preview
Go deeper on 2026-526884-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526884-39-00.